Royalty Pharma saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 68 to 72.
This proprietary rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the best stocks often have an RS Rating of at least 80 in the early stages of their moves. See if Royalty Pharma can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Royalty Pharma is building a consolidation with a 31.66 buy point. See if the stock can clear the breakout price in heavy trading.
In terms of top and bottom line numbers, the company has posted two quarters of increasing earnings growth. Sales growth has also increased over the same time frame. The company is expected to report its next quarterly numbers on or around Feb. 12.
Royalty Pharma holds the No. 16 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Halozyme Therapeutics and Neurocrine Biosciences are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
